Rheumatoid Arthritis News

Individuals who live closer to the equator develop rheumatoid arthritis at a younger age, a link that is likely explained by socioeconomic status, according to data published in the Annals of the Rheumatic Diseases.

Patients with rheumatoid arthritis who demonstrate lower disease activity are more likely to remain in LDA or remission after switching from combination therapy to monotherapy, according to data published in the Journal of Rheumatology.

Peresolimab 700 mg is superior to placebo in the treatment of moderate-to-severe rheumatoid arthritis, according to data published in the New England Journal of Medicine.

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

Patients with rheumatoid arthritis demonstrate a nearly 1.5-fold increased risk for developing Parkinson’s disease vs. those without RA, according to data published in JAMA Neurology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed concern level around COVID-19 in patients with RA at this stage of the pandemic, and whether or not patients with RA are urged to get fourth and fifth booster shots.

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discusses the role of JAK inhibitors in rheumatoid arthritis treatment, and growing understanding of their effects.

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discusses the links between depression and rheumatoid arthritis, a relationship that he says could work both ways.